The WHO Pandemic Agreement: A Guide to the First Global Treaty on Pandemic Preparedness and Equity

In May 2025, the global health landscape shifted when 124 nations voted at the 78th World Health Assembly to adopt the world's first Pandemic Agreement.[1][6]

The historic treaty was born directly from the collective trauma of the COVID-19 crisis, which claimed millions of lives and wiped out an estimated $13 trillion in global economic output.[3][7]

Driven by a mandate to prevent history from repeating itself, the agreement aims to build a robust international architecture that ensures future pandemic responses are coordinated, rapid, and fundamentally equitable.[1][6]

To address widespread public misconceptions, the final text of the treaty explicitly reaffirms national sovereignty. It dictates that the World Health Organization (WHO) holds no authority to impose lockdowns, border closures, or vaccine mandates on any sovereign state.[1][8]

Instead, the framework focuses on strengthening global supply chains, harmonizing regulatory approvals for medical products, and building early-warning surveillance networks to detect emerging threats before they cross borders.[1][7]

However, despite the triumphant adoption of the main text in 2025, the treaty remains in a state of diplomatic limbo as of mid-2026.[4][7]

The roadblock preventing the agreement from formally entering into force is a highly technical but deeply consequential operational annex known as the Pathogen Access and Benefit-Sharing (PABS) system.[4][5]

The PABS system is designed to solve the central inequity of the COVID-19 pandemic: the stark disconnect between the regions where novel viruses often emerge and the high-income nations where vaccines are predominantly manufactured and distributed.[5][7]

Under the proposed PABS framework, member states would be legally obligated to rapidly share physical samples and genetic sequence data of any new pathogens with pandemic potential through secure international databases.[5][8]

In exchange for this vital epidemiological data, a mandatory "benefit-sharing" mechanism would be activated. Manufacturers utilizing the PABS network to develop medical countermeasures would be required to allocate a portion of their output to global equity.[4][5]

The current working drafts of the annex suggest that during a declared pandemic emergency, 20% of real-time production of vaccines, therapeutics, and diagnostics would be diverted from standard commercial channels.[5][7]

Half of this allocation—10% of total production—would be donated directly to the WHO for rapid distribution to vulnerable populations, while the remaining 10% would be made available to developing nations at affordable, tiered pricing.[5]

Developing nations, primarily in the Global South, view this mandatory allocation as the non-negotiable cornerstone of the entire treaty, arguing that voluntary charity models failed them during the COVID-19 vaccine rollout.[4][7]

Conversely, representatives from the life sciences industry and several high-income nations have expressed concern that overly rigid, mandatory sharing rules could disincentivize rapid research and development investments during a fast-moving crisis.[2][5]

These complex ideological and economic disagreements caused member states to miss a critical May 2026 deadline to finalize the PABS annex at the 79th World Health Assembly.[4][5]

In response to the deadlock, the Intergovernmental Working Group (IGWG) was granted an extension, holding intensive, closed-door negotiations in Geneva through July 2026 in an attempt to bridge the remaining gaps.[1][7]

The urgency of these ongoing talks was underscored in June 2026, when WHO Director-General Tedros Adhanom Ghebreyesus and Brazilian President Luiz Inácio Lula da Silva issued a joint letter pleading for world leaders to finalize the annex.[2][3]

Their warning coincided with a newly declared Public Health Emergency of International Concern regarding an Ebola Bundibugyo outbreak in the Democratic Republic of the Congo—a stark reminder that the threat of emerging pathogens is constant.[2][5]

Until the PABS annex is finalized and attached to the main text, the Pandemic Agreement cannot be opened for formal signature, delaying the process of securing the 60 national ratifications required for the treaty to enter into force.[6][8]

As negotiators prepare for the next round of critical talks scheduled for September 2026, the global community faces a defining test: whether the hard-learned lessons of the last pandemic can be translated into binding, equitable international law before the next crisis arrives.[1][7]